However, two studies reported that one patient with chronic inflammatory demyelinating polyneuropathy experienced recurrence after anti-BCMA CAR T cells, and two patients with autoimmune hemolytic anemia, who had experienced recurrence after anti-CD19 CAR T cells, were successfully treated with a BCMA-Targeted T-Cell Engager.14 Here, TNFRSF17 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.